DK3265115T3 - Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud - Google Patents

Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud Download PDF

Info

Publication number
DK3265115T3
DK3265115T3 DK16759540.4T DK16759540T DK3265115T3 DK 3265115 T3 DK3265115 T3 DK 3265115T3 DK 16759540 T DK16759540 T DK 16759540T DK 3265115 T3 DK3265115 T3 DK 3265115T3
Authority
DK
Denmark
Prior art keywords
abaloparatide
alendronate
reduction
combined
bone fractures
Prior art date
Application number
DK16759540.4T
Other languages
English (en)
Inventor
Gary Hattersley
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56849024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3265115(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health Inc filed Critical Radius Health Inc
Application granted granted Critical
Publication of DK3265115T3 publication Critical patent/DK3265115T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
DK16759540.4T 2015-03-03 2016-03-03 Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud DK3265115T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562127729P 2015-03-03 2015-03-03
US201562165841P 2015-05-22 2015-05-22
US201562201564P 2015-08-05 2015-08-05
US201562239733P 2015-10-09 2015-10-09
US201662278762P 2016-01-14 2016-01-14
PCT/US2016/020787 WO2016141250A1 (en) 2015-03-03 2016-03-03 USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK

Publications (1)

Publication Number Publication Date
DK3265115T3 true DK3265115T3 (da) 2022-09-05

Family

ID=56849024

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16759540.4T DK3265115T3 (da) 2015-03-03 2016-03-03 Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud

Country Status (8)

Country Link
US (7) US20170065682A1 (da)
EP (2) EP4137147A3 (da)
JP (4) JP6755256B2 (da)
AU (2) AU2016226103A1 (da)
CA (1) CA2977812A1 (da)
DK (1) DK3265115T3 (da)
ES (1) ES2927067T3 (da)
WO (1) WO2016141250A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253674B2 (en) 2016-04-18 2021-07-29 Kindeva Drug Delivery L.P. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
AU2017367699B2 (en) * 2016-11-30 2023-12-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
MX2021007056A (es) * 2019-01-11 2021-09-10 Radius Health Inc Métodos para detectar anticuerpos neutralizadores de hormona paratiroidea (pth) y análogo de péptido relacionado con hormona paratiroidea (pthrp).
WO2020166561A1 (ja) 2019-02-14 2020-08-20 富士フイルム株式会社 骨折リスク評価値取得装置及びその作動方法並びに骨折リスク評価値取得プログラム
BR112022004462A2 (pt) * 2019-09-12 2022-05-31 Radius Health Inc Métodos para melhorar a fusão espinhal com abaloparatida
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US20220378881A1 (en) * 2021-05-25 2022-12-01 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
JP5815206B2 (ja) * 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2010022176A1 (en) * 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
RU2013151314A (ru) * 2011-04-22 2015-05-27 Радиус Хэлс, Инк. СПОСОБ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ РТН, РТНrР И РОДСТВЕННЫХ ПЕПТИДОВ
EP3369747A1 (en) * 2012-06-25 2018-09-05 The Brigham and Women's Hospital, Inc. Targeted theratpeutics
EP3359241B1 (en) * 2015-10-09 2021-04-14 Radius Health, Inc. Formulations of pthrp analogues, transdermal patches thereof, and uses thereof

Also Published As

Publication number Publication date
EP3265115A4 (en) 2019-05-22
US20170065682A1 (en) 2017-03-09
EP3265115A1 (en) 2018-01-10
CA2977812A1 (en) 2016-09-09
US20230381283A1 (en) 2023-11-30
US20200376088A1 (en) 2020-12-03
JP7049412B2 (ja) 2022-04-06
US20220125887A1 (en) 2022-04-28
WO2016141250A1 (en) 2016-09-09
US20200061160A1 (en) 2020-02-27
AU2016226103A1 (en) 2017-08-31
EP4137147A2 (en) 2023-02-22
JP2020189884A (ja) 2020-11-26
EP4137147A3 (en) 2023-04-05
US20230321199A1 (en) 2023-10-12
AU2020267182A1 (en) 2020-12-03
JP2023129523A (ja) 2023-09-14
ES2927067T3 (es) 2022-11-02
JP2022075999A (ja) 2022-05-18
EP3265115B1 (en) 2022-06-22
JP2018508530A (ja) 2018-03-29
US20170368148A1 (en) 2017-12-28
JP6755256B2 (ja) 2020-09-16

Similar Documents

Publication Publication Date Title
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3265115T3 (da) Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud
DK3294720T3 (da) Fremgangsmåde til fremstilling af terpinolenepoxid
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3119408T3 (da) Overfladereageret calciumkarbonat til desensibilisering af tænder
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3303618T3 (da) Fremgangsmåder til prognose af prostatacancer
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3524255T3 (da) Sammensætning til behandling af acne
DK3386531T3 (da) Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3307267T3 (da) Behandling af multipel sklerose
DK3166611T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3390422T3 (da) Krystalformer af lnt
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner